354 related articles for article (PubMed ID: 27053685)
1. Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons.
Bagher AM; Laprairie RB; Kelly ME; Denovan-Wright EM
Mol Pharmacol; 2016 Jun; 89(6):652-66. PubMed ID: 27053685
[TBL] [Abstract][Full Text] [Related]
2. Bidirectional allosteric interactions between cannabinoid receptor 1 (CB
Bagher AM; Laprairie RB; Toguri JT; Kelly MEM; Denovan-Wright EM
Eur J Pharmacol; 2017 Oct; 813():66-83. PubMed ID: 28734930
[TBL] [Abstract][Full Text] [Related]
3. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
[TBL] [Abstract][Full Text] [Related]
4. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.
Laprairie RB; Bagher AM; Kelly ME; Denovan-Wright EM
Mol Pharmacol; 2016 Mar; 89(3):364-75. PubMed ID: 26700564
[TBL] [Abstract][Full Text] [Related]
5. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
[TBL] [Abstract][Full Text] [Related]
6. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors.
Martín AB; Fernandez-Espejo E; Ferrer B; Gorriti MA; Bilbao A; Navarro M; Rodriguez de Fonseca F; Moratalla R
Neuropsychopharmacology; 2008 Jun; 33(7):1667-79. PubMed ID: 17957223
[TBL] [Abstract][Full Text] [Related]
7. Histone H3 phosphorylation is under the opposite tonic control of dopamine D2 and adenosine A2A receptors in striatopallidal neurons.
Bertran-Gonzalez J; Håkansson K; Borgkvist A; Irinopoulou T; Brami-Cherrier K; Usiello A; Greengard P; Hervé D; Girault JA; Valjent E; Fisone G
Neuropsychopharmacology; 2009 Jun; 34(7):1710-20. PubMed ID: 19158668
[TBL] [Abstract][Full Text] [Related]
8. Heteromer formation between cannabinoid type 1 and dopamine type 2 receptors is altered by combination cannabinoid and antipsychotic treatments.
Bagher AM; Young AP; Laprairie RB; Toguri JT; Kelly MEM; Denovan-Wright EM
J Neurosci Res; 2020 Dec; 98(12):2496-2509. PubMed ID: 32881145
[TBL] [Abstract][Full Text] [Related]
9. Modulation of A₂a receptor antagonist on D₂ receptor internalization and ERK phosphorylation.
Huang L; Wu DD; Zhang L; Feng LY
Acta Pharmacol Sin; 2013 Oct; 34(10):1292-300. PubMed ID: 23933651
[TBL] [Abstract][Full Text] [Related]
10. Formation of OX-1R/CB1R heteromeric complexes in embryonic mouse hypothalamic cells: Effect on intracellular calcium, 2-arachidonoyl-glycerol biosynthesis and ERK phosphorylation.
Imperatore R; Palomba L; Morello G; Spiezio AD; Piscitelli F; Marzo VD; Cristino L
Pharmacol Res; 2016 Sep; 111():600-609. PubMed ID: 27436148
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D2 and angiotensin II type 1 receptors form functional heteromers in rat striatum.
Martínez-Pinilla E; Rodríguez-Pérez AI; Navarro G; Aguinaga D; Moreno E; Lanciego JL; Labandeira-García JL; Franco R
Biochem Pharmacol; 2015 Jul; 96(2):131-42. PubMed ID: 25986885
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid 2 receptors regulate dopamine 2 receptor expression by a beta-arrestin 2 and GRK5-dependent mechanism in neuronal cells.
Franklin JM; Broseguini de Souza RK; Carrasco GA
Neurosci Lett; 2021 May; 753():135883. PubMed ID: 33838258
[TBL] [Abstract][Full Text] [Related]
13. Endocytosis following dopamine D
Shioda N; Yabuki Y; Wang Y; Uchigashima M; Hikida T; Sasaoka T; Mori H; Watanabe M; Sasahara M; Fukunaga K
Mol Psychiatry; 2017 Aug; 22(8):1205-1222. PubMed ID: 27922607
[TBL] [Abstract][Full Text] [Related]
14. GIV/Girdin activates Gαi and inhibits Gαs via the same motif.
Gupta V; Bhandari D; Leyme A; Aznar N; Midde KK; Lo IC; Ear J; Niesman I; López-Sánchez I; Blanco-Canosa JB; von Zastrow M; Garcia-Marcos M; Farquhar MG; Ghosh P
Proc Natl Acad Sci U S A; 2016 Sep; 113(39):E5721-30. PubMed ID: 27621449
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling.
Li J; Guo Y; Schroeder FA; Youngs RM; Schmidt TW; Ferris C; Konradi C; Akbarian S
J Neurochem; 2004 Sep; 90(5):1117-31. PubMed ID: 15312167
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease.
Laprairie RB; Kelly ME; Denovan-Wright EM
Neuropharmacology; 2013 Sep; 72():47-57. PubMed ID: 23602984
[TBL] [Abstract][Full Text] [Related]
17. Genetic or pharmacological depletion of cannabinoid CB1 receptor protects against dopaminergic neurotoxicity induced by methamphetamine in mice.
Dang DK; Shin EJ; Mai AT; Jang CG; Nah SY; Jeong JH; Ledent C; Yamamoto T; Nabeshima T; Onaivi ES; Kim HC
Free Radic Biol Med; 2017 Jul; 108():204-224. PubMed ID: 28363605
[TBL] [Abstract][Full Text] [Related]
18. G protein-mediated mitogen-activated protein kinase activation by two dopamine D2 receptors.
Choi EY; Jeong D; Park KW; Baik JH
Biochem Biophys Res Commun; 1999 Mar; 256(1):33-40. PubMed ID: 10066418
[TBL] [Abstract][Full Text] [Related]
19. Activation of CB1 inhibits NGF-induced sensitization of TRPV1 in adult mouse afferent neurons.
Wang ZY; McDowell T; Wang P; Alvarez R; Gomez T; Bjorling DE
Neuroscience; 2014 Sep; 277():679-89. PubMed ID: 25088915
[TBL] [Abstract][Full Text] [Related]
20. Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol.
Bertran-Gonzalez J; Bosch C; Maroteaux M; Matamales M; Hervé D; Valjent E; Girault JA
J Neurosci; 2008 May; 28(22):5671-85. PubMed ID: 18509028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
